SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
SEC Accession No. 0001129928-23-000048
Filing Date
2023-08-14
Accepted
2023-08-14 09:49:22
Documents
7
Period of Report
2023-06-30

Document Format Files

Seq Description Document Type Size
1 6-K q22023form6-k.htm 6-K 22465
2 EX-99.1 2023 SECOND QUARTER INTERIM FINANCIAL STATEMENTS ex991-interimfsjune302023.htm EX-99.1 363319
3 EX-99.2 2023 SECOND QUARTER MD&A ex992-q22023mda.htm EX-99.2 240452
4 EX-99.3 Q2 2023 CERTIFICATION CEO ex993-q22023certificationx.htm EX-99.3 14384
5 EX-99.4 Q2 2023 CERTIFICATION CFO ex994-q22023certificationx.htm EX-99.4 14281
6 oncolyticslogotaglineblueaa.jpg GRAPHIC 355294
7 q22023pipeline4a.jpg GRAPHIC 529098
  Complete submission text file 0001129928-23-000048.txt   1823641
Mailing Address 804, 322 - 11 AVENUE SW CALGARY A0 T2R 0C5
Business Address 804, 322 - 11 AVENUE SW CALGARY A0 T2R 0C5 4036707380
ONCOLYTICS BIOTECH INC (Filer) CIK: 0001129928 (see all company filings)

IRS No.: 000000000 | Fiscal Year End: 1231
Type: 6-K | Act: 34 | File No.: 001-38512 | Film No.: 231166902
SIC: 2834 Pharmaceutical Preparations